Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.42 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.42 |
| ▸ | PKM | P14618 | 5/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597102 | 0.92 | TSHR (0.47) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL6700175 | 0.92 | TSHR (0.47) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 | |
| Bromide SCHEMBL6703034 | 0.90 | TSHR (0.46) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6704096 | 0.90 | TSHR (0.46) | TSHRLMNAALDH1A1SMN1; SMN2PARP1 | |
| SCHEMBL6700167 | 0.72 | TSHR (0.62) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL12890455 | 0.70 | TSHR (0.54) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL24805051 | 0.70 | TSHR (0.62) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL2903952 | 0.69 | RAB9A (0.50) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL9891915 | 0.69 | TSHR (0.66) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL11096876 | 0.68 | TSHR (0.56) | TSHRLMNAALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068119-A1 | Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor | POSPISILIK KAREL (CZ) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068119-A1 | Process for resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole and compounds therefor | NOTUM, SLC5A6, WEE2 | TSHR 998/4885LMNA 3585/4885ALDH1A1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.